Gift of Life Biologics supplies allogeneic cellular starting material to cell and gene therapy developers, positioning itself as a source of GMP-compliant donor material for R&D and commercialization. The company operates a 32,000 sq. ft. facility in South Florida that includes a donor center, high-capacity apheresis collection facility, cellular therapy laboratory and biobank. It is backed by the Gift of Life Marrow Registry and is led by Chairman Stephen B. Siegel. The donor registry is accredited by the World Marrow Donor Association (WMDA), the apheresis center is accredited by the Association for the Advancement of Blood & Biotherapies (AABB), and the cellular therapy laboratory’s testing services are CLIA accredited. Commercialization of initial cellular starting material products was completed in Q4 2021, and Institutional Review Board approvals for procurement of mononuclear cells and mobilized stem cells were received in Q4 2021 and Q1 2022. The company focuses on providing regulated, accredited starting material to support developers' R&D and commercialization needs.

Total raised

$6M

Funding rounds

1

Latest round

Seed

Latest activity

Apr 2022